Please assess the completion status of the following clinical trial:

Trial Title: A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented clinical diagnosis and electrophysiological evidence of MMN~* Patients who have previously responded to intravenous immunoglobulin (IVIG) and have been on stable treatment with IVIG for at least 12 weeks prior to screening~* Patients treated with the equivalent of ≥0.4g/kg body weight (bw) IVIG per month~* Provision of informed consent by patient~Exclusion Criteria:~* Aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) concentration \>2.5 times the upper normal limit (UNL)~* Creatinine concentration \>1.5 times the UNL~* Known allergic reactions to blood products~* Any skin disease interfering with the assessment of injection site reactions~* Any other medical condition, which in the opinion of the investigator, might interfere with successful completion of the protocol~* Any condition likely to interfere with the evaluation of the study drug or satisfactory conduct of the trial~* Participation in a study with an investigational drug within three months prior to enrolment~* Patients treated with the equivalent of \>2.0g/kg bw IVIG per month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vivaglobin (Type: EXPERIMENTAL): Vivaglobin® is a 16% (160 mg/mL) liquid formulation of human normal immunoglobulin for subcutaneous infusion. Subjects will receive weekly infusions of Vivaglobin® at a weekly dosage calculated based on previous intravenous immunoglobulin treatment (between 0.1 to 0.5 g/kg body weight per week).

Based on this trial design, predict the completion outcome and termination type (if applicable).